New challenges have emerged regarding Medicare Part D which require a fundamental re-examination and modernization of the program.
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
A lot of Big Pharma companies were on the sidelines because they were unclear how cannabinoid therapeutics would be regulated by the FDA,” explains Alex Wasyl, CEO of Nexien BioPharma.
Across a dozen fields – from social psychology to endocrinology to chronobiology – researchers are assembling a new science of breaks. Their main finding: Leaders and their teams should be taking more breaks.
Whether it’s product promotion or pricing practices, biopharma’s inability to envision long-term consequences when implementing short-term decisions further handicaps what it is trying to do.
Bassil Dahiyat, Ph.D., president and CEO of Xencor, shares his perspective on why full-time equivalent (FTE) partnering deals are money losers.
Bassil Dahiyat, Ph.D., president and CEO of Xencor, a publicly traded biotech he founded right out of graduate school, shares three formative experiences gained as a first-time entrepreneur.
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
